Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 12/20 | 0.69 |
| ▸ | NPY1R | P25929 | 3/20 | 0.62 |
| ▸ | NPY2R | P49146 | 3/20 | 0.62 |
| ▸ | NPY4R | P50391 | 3/20 | 0.62 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399016 | 0.99 | GHSR (0.68) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL30618455 | 0.90 | NPY1R (0.57) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29849030 | 0.90 | NPY1R (0.57) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29373777 | 0.89 | NPY1R (0.74) | NPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29390038 | 0.88 | NPY1R (0.67) | NPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29546807 | 0.86 | GHSR (0.90) | GHSR | |
| SCHEMBL21641789 | 0.85 | NLN (0.69) | GHSR | |
| SCHEMBL29479454 | 0.84 | GHSR (0.67) | GHSR | |
| SCHEMBL26006253 | 0.83 | KISS1R (0.64) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL26006274 | 0.83 | KISS1R (0.64) | GHSRNPY1RNPY2RNPY4RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681776-A2 | ANTIMICROBIAL THERAPY | The Regents of the University of California (US) | 2026-01-21 | — | — | EP | claimed |
| US-20250339474-A1 | ANTIMICROBIAL THERAPY | UNIV CALIFORNIA (US) | 2025-11-06 | — | — | US | claimed |
| CN-119623017-A | Optimal design method based on double-motor mode switching rule | 吉林大学 | 2025-03-14 | — | — | CN | claimed |
| CN-115189354-A | Through type cophase power supply system structure of electrified railway | 西南交通大学 | 2022-10-14 | — | — | CN | claimed |
| EP-4719327-A1 | TOPICAL FORMULATION COMPRISING DELIQUESCENT SUBSTANCE | L'OREAL (FR) | 2026-04-08 | — | — | EP | disclosed |
| US-20260093537-A1 | TECHNIQUES FOR RESOURCE ALLOCATION AND MANAGEMENT | DELL PRODUCTS L.P. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681776-A2 | ANTIMICROBIAL THERAPY | The Regents of the University of California (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250356957-A1 | EMULATOR OF SUBCUTANEOUS ABSORPTION AND RELEASE | UNIV KANSAS (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250346913-A1 | NOVEL METHODS FOR IDENTIFICATION AND USE OF UPSTREAM OPEN READING FRAMES | GENXTRAITS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250339474-A1 | ANTIMICROBIAL THERAPY | UNIV CALIFORNIA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3849573-B1 | BACTERIOTHERAPY AGAINST PROPRIONIBACTERIUM ACNES FOR THE TREATMENT OF ACNE | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250270572-A1 | GENE EXPRESSION ELEMENTS AND SYSTEMS AND USE THEREOF | GENENEER LTD. (IL) | 2025-08-28 | — | — | US | disclosed |
| EP-3972619-A1 | COMPOSITION FOR TREATMENT, ALLEVIATION OR PROPHYLAXIS OF ACNE | Lactobio A/S (DK) | 2022-03-30 | — | — | EP | disclosed |
| CN-114245748-A | Gel composition comprising viable microorganisms | 莱托生物股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-216101498-U | Main and auxiliary box power assembly of double motors | 广西玉柴机器股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220064656-A1 | GENE EXPRESSION ELEMENTS AND SYSTEMS AND USE THEREOF | GENENEER LTD. (IL) | 2022-03-03 | — | — | US | disclosed |
| US-20220062354-A1 | TOPICAL FORMULATIONS FOR THE DELIVERY OF MICROBIALLY DERIVED MATERIALS | MATRISYS BIOSCIENCE, INC. | 2022-03-03 | — | — | US | disclosed |
| CN-114040770-A | Composition for treating, alleviating or preventing acne | 莱托生物股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20220038284-A1 | Testing and Other Data Communicated Using Trust Models In Decentralized and Distributed Systems | SAFELISHARE, INC. | 2022-02-03 | — | — | US | disclosed |
| JP-2022016613-A | GAME MACHINE | 株式会社三洋物産 | 2022-01-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260093537-A1 | TECHNIQUES FOR RESOURCE ALLOCATION AND MANAGEMENT | CLPP, DSTN, VSIR | GHSR 1153/4885NPY1R 1553/4885NPY2R 1483/4885 |
| US-20250339474-A1 | ANTIMICROBIAL THERAPY | LCT, HM13, ITCH | GHSR 300/4885NPY1R 2184/4885NPY2R 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.